AusperBio Therapeutics secures US$37M in Series A Financing

USA—AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company specializing in targeted oligonucleotide therapeutics, has successfully completed a US$37 million Series A funding round.

 This significant investment was spearheaded by existing investor InnoPinnacle Fund, with additional participation from new investors including Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital.

The proceeds from this financing will be strategically utilized to support the clinical development of AHB-137, AusperBio’s lead product candidate.

Additionally, the funds will also be directed towards advancing AusperBio’s proprietary Med-Oligo technology platform and expanding its product pipelines.

This dual focus on both the lead candidate and the technological platform underscores the company’s comprehensive approach to tackling chronic hepatitis B (CHB).

Commenting on the successful funding round, Dr. Guofeng Cheng, co-founder and CEO of AusperBio, expressed gratitude for the continued support from their existing investors and extended a warm welcome to the new investors joining the company.

He emphasized that this financing round marks a significant milestone, recognizing AusperBio’s scientific and clinical achievements to date, including the development of new therapeutics for CHB patients.

Moreover, Dr. Cheng highlighted that this funding, along with the recent Breakthrough Therapy Designation (BTD) from China’s Center for Drug Evaluation (CDE), positions AusperBio to rapidly advance the clinical development of AHB-137.

He noted that these combined efforts bring the company closer to providing a vital new treatment option for patients suffering from CHB, potentially transforming the treatment landscape for this chronic condition.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook